Daix (France), June 9, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that three abstracts have been selected for presentation at the upcoming International Liver Congress™ 2021 hosted by the European Association for the Study of the Liver (EASL), June 23-26, 2021. Inventiva will also host a KOL webcast event on June 29, 2021, focusing on the three abstracts, the current NASH field and Inventiva’s upcoming Phase III clinical trial on lanifibranor (further details below).

By A Silva